Dashboard
Manage Tickers

CERECerevel Therapeutics Holdin...

Nasdaq cerevel.com


$ 42.64 $ 0.16 (0.38 %)    

Monday, 29-Apr-2024 10:07:24 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 432.43 $ -0.68 (-0.16 %)
DIA $ 383.20 $ -0.10 (-0.03 %)
SPY $ 510.07 $ -0.19 (-0.04 %)
TLT $ 88.58 $ -0.08 (-0.09 %)
GLD $ 216.34 $ 0.29 (0.13 %)
$ 42.47
$ 42.48
$ 42.64 x 100
$ 0.00 x 0
$ 42.48 - $ 42.64
$ 19.59 - $ 43.59
680,906
na
6.88B
$ 1.27
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 02-27-2024 12-31-2023 10-K
2 11-01-2023 09-30-2023 10-Q
3 08-02-2023 06-30-2023 10-Q
4 05-03-2023 03-31-2023 10-Q
5 02-22-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-01-2022 06-30-2022 10-Q
8 05-10-2022 03-31-2022 10-Q
9 03-01-2022 12-31-2021 10-K
10 11-10-2021 09-30-2021 10-Q
11 08-11-2021 06-30-2021 10-Q
12 05-17-2021 03-31-2021 10-Q
13 03-24-2021 12-31-2020 10-K
14 11-16-2020 09-30-2020 10-Q
15 08-14-2020 06-30-2020 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

soon-to-be-acquired-cerevel-therapeutics-reveals-high-level-data-from-late-stage-parkinsons-disease-study
Soon To Be Acquired Cerevel Therapeutics R...
04/18/2024 17:44:09

Discover toplines results of Cerevel Therapeutics' Phase 3 TEMPO-3 trial for tavapadon in Parkinson's disease treatment...

cerevel-therapeutics-topline-results-from-phase-3-tempo-3-trial-for-tavapadon-for-parkinsons-disease-met-primary-endpoint-demonstrating-statistically-significant-increase-in-total-on-time-without-troublesome-dyskinesia-vs-placebo
Cerevel Therapeutics' Topline Results From...
04/18/2024 10:34:30

why-is-ulcerative-colitis-focused-landos-biopharma-stock-trading-higher-on-monday
Why Is Ulcerative Colitis-Focused Landos B...
03/25/2024 15:27:58

AbbVie seals deal with Landos Biopharma at $20.42/share, totaling $137.5 million plus CVR. Acquisition targets NX-13, promising...

mizuho-maintains-neutral-on-cerevel-therapeutics-hldg-raises-price-target-to-45
Mizuho Maintains Neutral on Cerevel Therap...
02/16/2024 23:46:50

Mizuho analyst Graig Suvannavejh maintains Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Neutral and raises the price targe...

this-analyst-is-bullish-on-biohavens-approach-in-neuro-psych-space
This Analyst Is Bullish On Biohaven's Appr...
02/16/2024 18:58:46

Biohaven's potential with RBC Capital Markets' optimistic outlook.. RBC sees blockbuster potential of $3.2 billion acro...

ubs-bullish-on-this-depression-drug-maker-says-alzheimers-agitation-data-is-attractive-catalyst
UBS Bullish On This Depression Drug Maker,...
02/06/2024 19:19:39

UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. P...

abbvie-lifts-long-term-outlook-for-new-immunology-drugs-even-as-q4-revenue-and-profit-fall
AbbVie Lifts Long-Term Outlook For New Imm...
02/02/2024 16:12:37

AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outloo...

abbvies-transformational-2023-analyst-anticipates-growth-in-2024-amid-competitive-pressures
AbbVie's Transformational 2023, Analyst An...
01/29/2024 19:04:56

AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, st...

5-biotech-stocks-that-should-be-on-investors-radar-as-jpmorgan-healthcare-conference-gets-underway-monday
5 Biotech Stocks That Should Be On Investo...
01/08/2024 11:04:30

The rebound by biopharma stocks in 2023 and the pickup in M&A news flow makes the 2024 JPMorgan Healthcare conference even ...

upward-trajectory-for-biotechpharma-ma-sector-trends-towards-pre-pandemic-levels-forecasts-positive-for-2024
Upward Trajectory For Biotech/Pharma M&A: ...
12/29/2023 12:04:52

According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 bill...

jp-morgan-maintains-neutral-rating-for-cerevel-therapeutics-hldg-heres-what-you-need-to-know
JP Morgan Maintains Neutral Rating for Cer...
12/28/2023 17:00:16

jp-morgan-maintains-neutral-on-cerevel-therapeutics-hldg-raises-price-target-to-45
JP Morgan Maintains Neutral on Cerevel The...
12/28/2023 10:52:12

JP Morgan analyst Jessica Fye maintains Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Neutral and raises the price target f...

tesla-to-rally-around-38-here-are-10-top-analyst-forecasts-for-friday
Tesla To Rally Around 38%? Here Are 10 Top...
12/22/2023 12:33:42

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...

jefferies-downgrades-cerevel-therapeutics-hldg-to-hold-raises-price-target-to-45
Jefferies Downgrades Cerevel Therapeutics ...
12/22/2023 10:24:46

Jefferies analyst Michael Yee downgrades Cerevel Therapeutics Hldg (NASDAQ:CERE) from Buy to Hold and raises the price targe...

10-health-care-stocks-with-whale-alerts-in-todays-session
10 Health Care Stocks With Whale Alerts In...
12/11/2023 17:35:24

td-cowen-downgrades-cerevel-therapeutics-hldg-to-market-perform-announces-45-price-target
TD Cowen Downgrades Cerevel Therapeutics H...
12/08/2023 10:13:32

TD Cowen analyst Joseph Thome downgrades Cerevel Therapeutics Hldg (NASDAQ:CERE) from Outperform to Market Perform and annou...

abbvies-new-9b-neuroscience-space-deal-might-attract-ftc-scrutiny-analyst-signals
AbbVie's New $9B Neuroscience Space Deal M...
12/07/2023 20:19:19

Wednesday, AbbVie Inc (NYSE: ABBV) agreed to acquire Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) for a total equity value ...

hc-wainwright--co-downgrades-cerevel-therapeutics-hldg-to-neutral-raises-price-target-to-45
HC Wainwright & Co. Downgrades Cerevel The...
12/07/2023 19:33:09

HC Wainwright & Co. analyst Douglas Tsao downgrades Cerevel Therapeutics Hldg (NASDAQ:CERE) from Buy to Neutral and rais...

why-methode-electronics-shares-are-trading-lower-by-over-14-here-are-other-stocks-moving-in-thursdays-mid-day-session
Why Methode Electronics Shares Are Trading...
12/07/2023 18:13:56

Shares of Methode Electronics, Inc (NYSE: MEI) fell sharply during Thursday’s session following weak quarterly earnings.

why-cerevel-therapeutics-stock-is-higher
Why Cerevel Therapeutics Stock Is Higher
12/07/2023 17:05:44

Cerevel Therapeutics Holdings, Inc.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION